Related Experiment Video
Updated: Feb 12, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status
Aman Chauhan1, Susanne M Arnold1, Jill Kolesar1
1Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
Introduction:
Large cell neuroendocrine carcinomas (LCNEC) are a group of rare high grade neuroendocrine tumors that often behave clinically like small cell carcinoma (SCLC) and are treated as such. No major advancement in the management of these tumors has occurred in the last 30 years.
Methods:
We present a case series of three cases from Markey Cancer center along with a review of 13 published cases in the literature wherein immune-checkpoint inhibitors were utilized in the management of LCNEC.
Results:
Immune-checkpoint inhibitors might have clinical activity in LCNEC.
Conclusion:
Role of immune-checkpoint inhibitors should be explored in prospective LCNEC clinical trials. We summarize current evidence regarding use of immune checkpoint inhibitors in the treatment of LCNEC.
More Related Videos
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
What is the Immune System?
Marcia's Theory of Identity Status
Cell-mediated Immune Responses
Cells of the Adaptive Immune Response

